Autologous Stem Cell Therapy for Inherited and Acquired Retinal Disease

Overview

Journal Regen Med

Specialty Biotechnology

Date 2018 Jan 24

PMID 29360008

Citations 7

Authors

Mary Ben L Apatoff

Jesse D Sengillo

Eugenia C White

Mathieu F Bakhoum

Alexander G Bassuk

Vinit B Mahajan

Stephen H Tsang

Affiliations

Soon will be listed here.

Abstract

The mammalian retina, derived from neural ectoderm, has little regenerative potential. For conditions where irreversible retinal pigment epithelium or photoreceptor cell loss occurs, advanced techniques are required to restore vision. Inherited retinal dystrophies and some acquired conditions, such as age-related macular degeneration, have a similar end result of photoreceptor cell death leading to debilitating vision loss. These diseases stand to benefit from future regenerative medicine as dietary recommendations and current pharmacologic therapy only seek to prevent further disease progression. Cell-based strategies, such as autologously derived induced pluripotent stem cells, have come a long way in overcoming previous technical and ethical concerns. Clinical trials for such techniques are already underway. These trials and the preceding preclinical studies will be discussed in the context of retinal disease.

Citing Articles

Regenerative rehabilitation: a novel multidisciplinary field to maximize patient outcomes.

Deng C, Aldali F, Luo H, Chen H Med Rev (2021). 2024; 4(5):413-434.

PMID: 39444794 PMC: 11495474. DOI: 10.1515/mr-2023-0060.

Evaluation of the efficacy of subtenon autologous platelet-rich plasma therapy in patients with retinitis pigmentosa and factors affecting response to the treatment.

Sahli E, Ozmert E, Gunel M, Atilla H Int Ophthalmol. 2024; 44(1):388.

PMID: 39313744 DOI: 10.1007/s10792-024-03305-4.

Towards Stem/Progenitor Cell-Based Therapies for Retinal Degeneration.

Liu H, Lu S, Chen M, Gao N, Yang Y, Hu H Stem Cell Rev Rep. 2024; 20(6):1459-1479.

PMID: 38809490 DOI: 10.1007/s12015-024-10740-4.

Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues.

de Jongh D, Massey E, Cronin A, Schermer M, Bunnik E Transpl Int. 2022; 35:10751.

PMID: 36388425 PMC: 9659568. DOI: 10.3389/ti.2022.10751.

Interaction Between Mesenchymal Stem Cells and Retinal Degenerative Microenvironment.

Lin Y, Ren X, Chen Y, Chen D Front Neurosci. 2021; 14:617377.

PMID: 33551729 PMC: 7859517. DOI: 10.3389/fnins.2020.617377.

References

Zhao T, Zhang Z, Rong Z, Xu Y . Immunogenicity of induced pluripotent stem cells. Nature. 2011; 474(7350):212-5. DOI: 10.1038/nature10135. View

Li Y, Wu W, Hsu C, Nguyen H, Tsai Y, Chan L . Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects. Mol Ther. 2014; 22(9):1688-97. PMC: 4435479. DOI: 10.1038/mt.2014.100. View

Luo J, Baranov P, Patel S, Ouyang H, Quach J, Wu F . Human retinal progenitor cell transplantation preserves vision. J Biol Chem. 2014; 289(10):6362-6371. PMC: 3945303. DOI: 10.1074/jbc.M113.513713. View

Li Y, Tsai Y, Hsu C, Erol D, Yang J, Wu W . Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med. 2012; 18:1312-9. PMC: 3521789. DOI: 10.2119/molmed.2012.00242. View

Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T . Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med. 2017; 376(11):1038-1046. DOI: 10.1056/NEJMoa1608368. View

Pearson R, Barber A, Rizzi M, Hippert C, Xue T, West E . Restoration of vision after transplantation of photoreceptors. Nature. 2012; 485(7396):99-103. PMC: 3888831. DOI: 10.1038/nature10997. View

Boudreault K, Justus S, Lee W, Mahajan V, Tsang S . Complication of Autologous Stem Cell Transplantation in Retinitis Pigmentosa. JAMA Ophthalmol. 2016; 134(6):711-2. DOI: 10.1001/jamaophthalmol.2016.0803. View

Shirai H, Mandai M, Matsushita K, Kuwahara A, Yonemura S, Nakano T . Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration. Proc Natl Acad Sci U S A. 2015; 113(1):E81-90. PMC: 4711854. DOI: 10.1073/pnas.1512590113. View

Palomo A, McLenachan S, Chen F, da Cruz L, Dilley R, Requena J . Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration. Fibrogenesis Tissue Repair. 2015; 8:9. PMC: 4432516. DOI: 10.1186/s13069-015-0026-9. View

10.

Kuriyan A, Albini T, Townsend J, Rodriguez M, Pandya H, Leonard 2nd R . Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. N Engl J Med. 2017; 376(11):1047-1053. PMC: 5551890. DOI: 10.1056/NEJMoa1609583. View

11.

Gill K, Hewitt A, Davidson K, Pebay A, Wong R . Methods of Retinal Ganglion Cell Differentiation From Pluripotent Stem Cells. Transl Vis Sci Technol. 2015; 3(4):7. PMC: 4356355. DOI: 10.1167/tvst.3.3.7. View

12.

Peyman G, Blinder K, Paris C, Alturki W, Nelson Jr N, Desai U . A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg. 1991; 22(2):102-8. View

13.

Garg A, Yang J, Lee W, Tsang S . Stem Cell Therapies in Retinal Disorders. Cells. 2017; 6(1). PMC: 5371869. DOI: 10.3390/cells6010004. View

14.

Lamba D, McUsic A, Hirata R, Wang P, Russell D, Reh T . Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS One. 2010; 5(1):e8763. PMC: 2808350. DOI: 10.1371/journal.pone.0008763. View

15.

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

16.

Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S . Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013; 112(3):523-33. DOI: 10.1161/CIRCRESAHA.111.256149. View

17.

Binder S, Krebs I, Hilgers R, Abri A, Stolba U, Assadoulina A . Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial. Invest Ophthalmol Vis Sci. 2004; 45(11):4151-60. DOI: 10.1167/iovs.04-0118. View

18.

Yao J, Tucker B, Zhang X, Checa-Casalengua P, Herrero-Vanrell R, Young M . Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials. 2010; 32(4):1041-50. DOI: 10.1016/j.biomaterials.2010.09.063. View

19.

Sugita S . Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp (Warsz). 2009; 57(4):263-8. DOI: 10.1007/s00005-009-0030-0. View

20.

Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K . Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009; 458(7239):771-5. PMC: 2667910. DOI: 10.1038/nature07864. View